Measurable body composition changes usually become apparent by weeks 2-4, with progressive improvements continuing through weeks 4-12 of consistent use
Daiichi Sankyo supported its NDA, accepted last Fall, with data from a Phase III trial that showed the quizartinib regimencombined with standard induction and consolidation chemotherapy and continued as a single agent)reduced the risk of death by 22.4% compared to patients on chemotherapy alone
References: Seiwerth, S., Rucman, R., Turkovic, B., Sever, M., Klicek, R., Radic, B., & Sikiric, P
There is no completed human weight-loss trial of 5-Amino-1MQ, so the effect in people remains unproven despite heavy marketing
Naturally occurring in the body, GHK-CU plays a central role in cellular renewal pathways and structural protein synthesis